Symbols / LIMN $0.24 +1.20%

LIMN Chart
About

Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical company that develops novel cancer therapies. It is developing CD47, a high affinity humanized anti CD47 antibody that has the potential to translate into clinic for CD47 SIRPa blocking and restoring the anti-tumor function of innate immune cells without inducing hemagglutination or hemolysis. The company was founded in 2018 is based in LA Palma, California.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 9.28M
Enterprise Value 7.10M Income -2.27M Sales —
Book/sh -0.06 Cash/sh 0.03 Dividend Yield —
Payout 0.00% Employees — IPO —
P/E — Forward P/E — PEG —
P/S — P/B -3.87 P/C —
EV/EBITDA — EV/Sales — Quick Ratio 0.25
Current Ratio 0.42 Debt/Eq — LT Debt/Eq —
EPS (ttm) -0.16 EPS next Y — EPS Growth —
Revenue Growth — Earnings — ROA -48.06%
ROE — ROIC — Gross Margin 0.00%
Oper. Margin 0.00% Profit Margin 0.00% Shs Outstand 39.33M
Shs Float 17.53M Short Float — Short Ratio 0.14
Short Interest — 52W High 33.66 52W Low 0.21
Beta 0.50 Avg Volume 8.94M Volume 980.69K
Target Price — Recom None Prev Close $0.23
Price $0.24 Change 1.20%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$0.24
Latest analyst target
3. DCF / Fair value
$-0.31
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.24
Low
—
High
—
Mean
—
Insider Transactions

No recent insider transactions.

Financials
Line Item2023-12-312022-12-31
TaxEffectOfUnusualItems0.000.00
TaxRateForCalcs0.000.00
NormalizedEBITDA-4.81M-2.71M
NetIncomeFromContinuingOperationNetMinorityInterest-4.98M-2.93M
EBITDA-4.81M-2.71M
EBIT-4.81M-2.71M
NetInterestIncome-165.00K-219.00K
InterestExpense175.00K219.00K
InterestIncome10.00K0.00
NormalizedIncome-4.98M-2.93M
NetIncomeFromContinuingAndDiscontinuedOperation-4.98M-2.93M
TotalExpenses4.82M2.71M
TotalOperatingIncomeAsReported-4.82M-2.71M
DilutedAverageShares26.01M26.01M
BasicAverageShares26.01M26.01M
DilutedEPS-0.19-0.11
BasicEPS-0.19-0.11
DilutedNIAvailtoComStockholders-4.98M-2.93M
NetIncomeCommonStockholders-4.98M-2.93M
NetIncome-4.98M-2.93M
NetIncomeIncludingNoncontrollingInterests-4.98M-2.93M
NetIncomeContinuousOperations-4.98M-2.93M
PretaxIncome-4.98M-2.93M
NetNonOperatingInterestIncomeExpense-165.00K-219.00K
InterestExpenseNonOperating175.00K219.00K
InterestIncomeNonOperating10.00K0.00
OperatingIncome-4.82M-2.71M
OperatingExpense4.82M2.71M
ResearchAndDevelopment3.76M1.85M
SellingGeneralAndAdministration1.06M856.00K
GeneralAndAdministrativeExpense1.06M856.00K
OtherGandA1.06M856.00K
TotalRevenue0.000.00
OperatingRevenue0.000.00
Line Item2023-12-312022-12-31
OrdinarySharesNumber26.01M26.01M
ShareIssued26.01M26.01M
NetDebt15.62M11.45M
TotalDebt16.05M16.50M
TangibleBookValue-15.79M-10.81M
InvestedCapital256.00K5.69M
WorkingCapital-15.79M-10.81M
NetTangibleAssets0.000.00
CommonStockEquity-15.79M-10.81M
TotalCapitalization-15.79M-10.81M
TotalEquityGrossMinorityInterest-15.79M-10.81M
StockholdersEquity0.000.00
RetainedEarnings-25.12M-20.14M
TotalPartnershipCapital-15.79M-10.81M
GeneralPartnershipCapital4.61M5.16M
LimitedPartnershipCapital4.71M4.17M
TotalLiabilitiesNetMinorityInterest18.04M17.65M
TotalNonCurrentLiabilitiesNetMinorityInterest0.000.00
CurrentLiabilities18.04M17.65M
CurrentDebtAndCapitalLeaseObligation16.05M16.50M
CurrentDebt16.05M16.50M
OtherCurrentBorrowings16.05M16.50M
PayablesAndAccruedExpenses1.99M1.15M
CurrentAccruedExpenses616.00K441.00K
InterestPayable616.00K441.00K
Payables1.37M712.00K
OtherPayable242.00K
DuetoRelatedPartiesCurrent437.00K204.00K
AccountsPayable933.00K508.00K
TotalAssets2.24M6.84M
TotalNonCurrentAssets1.00K1.00K
NetPPE1.00K1.00K
CurrentAssets2.24M6.84M
OtherCurrentAssets22.00K10.00K
CurrentDeferredAssets840.00K0.00
PrepaidAssets0.001.68M
Receivables945.00K100.00K
DuefromRelatedPartiesCurrent126.00K100.00K
LoansReceivable819.00K0.00
CashCashEquivalentsAndShortTermInvestments434.00K5.05M
CashAndCashEquivalents434.00K5.05M
CashFinancial434.00K5.05M
Line Item2023-12-312022-12-31
FreeCashFlow-3.35M-869.00K
RepurchaseOfCapitalStock0.00-700.00K
RepaymentOfDebt-3.86M-7.03M
IssuanceOfDebt3.41M9.44M
IssuanceOfCapitalStock0.004.20M
InterestPaidSupplementalData0.00503.00K
IncomeTaxPaidSupplementalData0.000.00
EndCashPosition434.00K5.05M
BeginningCashPosition5.05M0.00
ChangesInCash-4.61M5.05M
FinancingCashFlow-450.00K5.92M
CashFlowFromContinuingFinancingActivities-450.00K5.92M
NetCommonStockIssuance0.003.50M
CommonStockPayments0.00-700.00K
CommonStockIssuance0.004.20M
NetIssuancePaymentsOfDebt-450.00K2.42M
NetShortTermDebtIssuance-450.00K2.42M
ShortTermDebtPayments-3.86M-7.03M
ShortTermDebtIssuance3.41M9.44M
InvestingCashFlow-819.00K0.00
CashFlowFromContinuingInvestingActivities-819.00K0.00
NetOtherInvestingChanges-819.00K
OperatingCashFlow-3.35M-869.00K
CashFlowFromContinuingOperatingActivities-3.35M-869.00K
ChangeInWorkingCapital1.64M1.16M
ChangeInOtherWorkingCapital-840.00K
ChangeInOtherCurrentAssets-12.00K-10.00K
ChangeInPayablesAndAccruedExpense807.00K216.00K
ChangeInAccruedExpense175.00K109.00K
ChangeInInterestPayable175.00K109.00K
ChangeInPayable632.00K107.00K
ChangeInAccountPayable425.00K89.00K
ChangeInPrepaidAssets1.68M953.00K
OtherNonCashItems900.00K
NetIncomeFromContinuingOperations-4.98M-2.93M
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Public Trades for LIMN
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status